Knight Capital Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Knight Capital Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$2.45M	Buy	+10,887	New	+$2.54M	0.05%	428

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Knight Capital Group's REGN Position: Q2 2013 in Review

Knight Capital Group opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2013: 10,887 shares worth $2.45M. The stake represents 0.05% of the portfolio and ranks #428 among its holdings.

371 funds tracked by Wall St. Rank hold REGN as of Q2 2013.

Knight Capital Group held 10,887 shares of Regeneron Pharmaceuticals worth $2.45M as of Q2 2013.
Regeneron Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
Regeneron Pharmaceuticals made up 0.05% of Knight Capital Group's portfolio in Q2 2013, its #428 holding.
371 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.